Skip To The Main Content
 

Shift Pharmaceuticals

Shift Pharmaceuticals is a startup drug development company with a platform technology for utilizing a Morpholino based Antisense Oligos (MAO) for treatment of neurodegenerative diseases. The core platform has been validated (with peer-reviewed publications) by our academic partners at The University of Missouri targeting Spinal Muscular Atrophy (SMA), which is our initial clinical focus. Intellectual property has been filed by the University and approved by the USPTO.

Executive Summary 

Originating Institution:

University of Missouri - Columbia

Team:

Steve O'Connor, CEO
Chris Lorson, CSO
Paul Marcos, Director of R&D
 

 

Intellectual Property:

Patents have been filed and approved by University of Missouri - Columbia and exclusively licensed to Shift.

Current Status

Incorporated
CEO

Needs

Capital
Advisors
Licensing Opportunities
Strategic Partnerships

For more information on this company, please fill out the form below or contact Jim Baxendale, baxendalej@umkc.edu.